SARTORIUS Aktiengesellschaft
ISIN: DE0007165631
WKN: 716563
16 September 2026 08:32AM

EQS-News: Sartorius and NIBRT announce partnership: Pioneering dedicated training center for intensified and continuous bioprocessing

SARTORIUS Aktiengesellschaft · ISIN: DE0007165631 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2399636

EQS-News: SARTORIUS Aktiengesellschaft / Key word(s): Alliance
Sartorius and NIBRT announce partnership: Pioneering dedicated training center for intensified and continuous bioprocessing (news with additional features)

16.09.2026 / 08:32 CET/CEST
The issuer is solely responsible for the content of this announcement.


Göttingen, Germany | Dublin, Ireland | September 16, 2026

Sartorius and NIBRT announce partnership:
Pioneering dedicated training center for intensified and continuous bioprocessing
 
  • Collaboration with National Institute for Bioprocessing Research and Training will enable practical training in next-generation biomanufacturing
  • Facility will be equipped with end-to-end continuous process platform Pionic by Sartorius
  • Partnership to strengthen global workforce readiness and accelerate industry transition toward more efficient and sustainable biopharmaceutical production

The life science group Sartorius and the National Institute for Bioprocessing Research and Training (NIBRT) are partnering to establish the world's most comprehensive training center for intensified and fully continuous bioprocessing in Dublin, Ireland. Starting in the fourth quarter of 2026, the center will serve as a hub for practical training and knowledge sharing to help the biopharmaceutical industry adopt intensified, digitalized and continuous manufacturing processes.

As part of the collaboration, Sartorius will equip NIBRT with its state-of-the-art Pionic technology – an end-to-end modular cGMP platform for integrated continuous bioprocessing with advanced analytics and digital tools. Through the collaboration, the new facility is expected to provide more than 1,000 scientists, engineers and students each year with hands-on experience in intensified upstream and downstream processes designed for efficiency, flexibility and sustainability.

“As biopharma manufacturing undergoes a major shift from batch processes toward more efficient, continuous processes, Sartorius is once again at the forefront of this transformation. While technological innovation is the first step, training current and future engineers and operators is critical to making the change a reality,” said René Fáber, Head of the Bioprocess Solutions Division and Member of the Executive Board at Sartorius. “Our partnership with NIBRT underscores Sartorius’ commitment to building global capabilities and accelerating the adoption of innovative and sustainable bioprocessing technologies.”

“This collaboration marks a significant step in advancing workforce training and supporting the transition toward intensified and connected manufacturing,” said Darrin Morrissey, CEO of NIBRT. “By integrating the Pionic platform into our training facility, we will give biopharma professionals the chance to gain first-hand experience with cutting-edge technologies that drive process efficiency and performance.”

The Process Intensification Training Center will become a key element of NIBRT’s global training and education network, serving industry professionals and academic partners in Ireland, Europe and worldwide. Beyond training, the center will also enable collaborative research and pilot-scale demonstrations, strengthening the global biomanufacturing ecosystem.


A profile of Sartorius
Sartorius is a leading international partner to biopharmaceutical research and manufacturing. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Germany-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees are working for customers around the globe.

Visit our newsroom or follow Sartorius on LinkedIn.


A profile of NIBRT
The National Institute for Bioprocessing Research and Training (NIBRT) is a world-leading institute based in Dublin, Ireland, that provides training and research solutions in partnership with the biopharmaceutical manufacturing industry and academic community. Established to support the growth of the biopharma sector, NIBRT offers a unique learning environment replicating a modern bioprocessing facility and delivers industry-aligned programs to thousands of trainees annually. Through its partnerships with global biopharma companies, academic institutions and technology providers, NIBRT plays a pivotal role in advancing innovation, skills and excellence in bioprocessing worldwide.


Contact
Verena Sattel
External Communications
+49 551 308 9261
verena.sattel@sartorius.com
 

Additional features:

File: Sartorius and NIBRT announce partnership: Pioneering dedicated training center for intensified and continuous bioprocessing | Media Release


16.09.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: SARTORIUS Aktiengesellschaft
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: info@sartorius.com
Internet: www.sartorius.com
ISIN: DE0007165631, DE0007165607
WKN: 716563, 716560
Indices: MDAX, TecDAX
Listed: Regulated Market in Hanover; Regulated Unofficial Market in Dusseldorf, Munich, Stuttgart, Tradegate BSX
LEI Code: 529900EQV2DY4FOAMU38
EQS News ID: 2399636

 
End of News EQS News Service

2399636  16.09.2026 CET/CEST

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2020 2021 2022 2023 2024 2025 2026e
Sales1 2.335,66 3.449,22 4.174,70 3.395,70 3.380,70 3.538,10 3.805,00
EBITDA1,2 636,70 1.134,26 1.410,40 962,70 945,30 1.051,60 1.165,00
EBITDA-Margin3 27,26 32,89 33,78 28,35 27,96 29,72 30,62
EBIT1,4 456,11 903,16 1.064,80 503,90 530,00 542,60 565,00
EBIT-Margin5 19,53 26,18 25,51 14,84 15,68 15,34 14,85
Net Profit (Loss)1 299,56 426,98 913,10 290,60 137,40 230,40 250,00
Net-Margin6 12,83 12,38 21,87 8,56 4,06 6,51 6,57
Cashflow1,7 511,53 865,81 734,20 853,60 976,00 837,00 860,00
Earnings per share8 4,38 8,09 9,58 4,95 5,30 4,79 5,30
Dividend per share8 0,71 1,26 1,44 0,74 0,74 0,74 1,44
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: PricewaterhouseCoopers

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Sartorius VZ
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
716563 DE0007165631 AG 16.084,22 Mio € 10.07.1990 Halten 9F3FHV2Q+JW
* * *
PE 2027e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
39,77 40,89 0,97 54,86 6,73 21,35 4,55
Dividends
Dividend '2024
in €
Dividend '2025
in €
Dividend '2026e
in €
Div.-Yield '2026e
in %
0,74 0,74 1,44 0,60%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
26.03.2026 23.04.2026 23.07.2026 22.10.2026 16.02.2026
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+4,70%
238,60 €
ATH 631,60 €
+2,05% +2,25% -3,48% +20,54% +3.968,20%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2026          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2026 by Gereon Kruse #BGFL